South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

Similarly, Eli Lilly licensed Rznomics’ trans-splicing ribozyme platform for treating hearing loss in a $1.3bn agreement. These transactions highlight Korea’s growing influence in drug delivery and ...